
A groundbreaking preclinical study from Yale School of Medicine published in Science Translational Medicine reveals that an existing blood-thinning medication may stop the progression of osteoarthritis. Currently, modern human medical science lacks approved disease-modifying therapies capable of reversing cartilage breakdown, relying instead on pain management. Yale researchers uncovered a dual-targeting biological mechanism that protects joint tissue from structural degeneration, offering a promising pathway toward preventive osteoarthritis treatment for millions of patients worldwide.